GlassScriptPhysician profile
Lawrence C Taylor
NPI 1699771873
$2,083.45
in general payments reported to CMS, 2019-2025
24 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $187 · 2021: $182 · 2022: $224 · 2023: $246 · 2024: $509 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $368.70 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Alcon Vision LLC | $319.54 | 2019-2025 | Clareon, Rocklatan |
| Abbvie INC. | $310.00 | 2023-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $165.54 | 2019-2022 | |
| Horizon Therapeutics Plc | $129.19 | 2019-2023 | Tepezza |
| Merz North America, INC. | $122.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.48 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $69.61 | 2020-2025 | Acthar |
| Dompe US, INC. | $68.99 | 2024 | Oxervate |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.14 | 2022-2023 | Trulance |
| Stryker Corporation | $47.51 | 2025 | Pangea |
| Bausch & Lomb Americas INC. | $40.78 | 2022-2023 | Doctors Allergy Formula |
| Glaukos Corporation | $31.92 | 2024 | Radius |
| Harrow Eye, LLC | $27.66 | 2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.35 | 2020-2022 | |
| Thea Pharma INC. | $27.25 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $26.10 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $24.98 | 2021 | |
| Lkc Technologies, INC. | $20.70 | 2024 | |
| Eyevance Pharmaceuticals LLC | $20.01 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.46 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $14.35 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.